biolinerx ltd: Live & Latest News Updates : Vimarsana.com

BioLineRx : Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER ...

BioLineRx (NASDAQ:BLRX) Lifted to Sell at StockNews.com

StockNews.com upgraded shares of BioLineRx (NASDAQ:BLRX – Free Report) to a sell rating in a report published on Tuesday morning. Separately, HC Wainwright reissued a buy rating and issued a $21.00 price objective on shares of BioLineRx in a research note on Wednesday, April 17th. View Our Latest Analysis on BioLineRx BioLineRx Stock Performance NASDAQ:BLRX […]

StockNews.com Upgrades BioLineRx (NASDAQ:BLRX) to Sell

BioLineRx (NASDAQ:BLRX – Get Free Report) was upgraded by investment analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Tuesday. Separately, HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of BioLineRx in a report on Wednesday, April 17th. Check Out Our […]

BioLineRx (NASDAQ:BLRX) Upgraded at StockNews.com

BioLineRx (NASDAQ:BLRX – Get Free Report) was upgraded by equities research analysts at StockNews.com to a “sell” rating in a research report issued on Tuesday. Separately, HC Wainwright restated a “buy” rating and set a $21.00 target price on shares of BioLineRx in a research note on Wednesday, April 17th. Check Out Our Latest Report […]

BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement

/PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare...

BioLineRx (BLRX) Announces 7.5M Share Offering at $0.80/sh

BioLineRx Announces $6 Million Registered Direct Offering

BioLineRx (NASDAQ:BLRX) Earns Buy Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of BioLineRx (NASDAQ:BLRX – Free Report) in a research report report published on Tuesday morning, Benzinga reports. HC Wainwright currently has a $21.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for BioLineRx’s Q1 2024 earnings at ($0.29) EPS, Q2 2024 earnings at […]

BioLineRx : Form 20-F/A (Amendment No. 1 -March 28, 2024 at 05:36 am EDT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F/A ...

BioLineRx (NASDAQ:BLRX) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright reiterated their buy rating on shares of BioLineRx (NASDAQ:BLRX – Free Report) in a report issued on Tuesday, Benzinga reports. They currently have a $21.00 price target on the biotechnology company’s stock. Separately, StockNews.com upgraded shares of BioLineRx to a sell rating in a report on Monday, December 4th. View Our Latest Research […]